Jancee Dunn / nytimes - Hint: You may need to buy new shoes.
AI Summary: Phase III DESTINY‑Lung04 data show trastuzumab deruxtecan (Enhertu) significantly prolongs progression‑free survival as first‑line therapy for HER2‑mutant non‑small cell lung cancer. Investigators hail the efficacy signal, but oncologists caution that longer follow‑up is needed to determine whether the PFS benefit will translate into overall survival advantage.
90 days, weeks are vertical, left is older; hover for info, click to see that day's coverage.
StackHealth RSS
StackHealth Time Machine
NorthFeed Inc. Terms and Conditions / Privacy Policy
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.